An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices

Podsumowanie

To address mechanisms of demyelination and neuronal apoptosis in cortical lesions of inflammatory demyelinating disorders, different animal models are used. We here describe an ex vivo approach by using oligodendrocyte-specific CD8⁺ T-cells on brain slices, resulting in oligodendroglial and neuronal death. Potential applications and limitations of the model are discussed.

Streszczenie

Death of oligodendrocytes accompanied by destruction of neurons and axons are typical histopathological findings in cortical and subcortical grey matter lesions in inflammatory demyelinating disorders like multiple sclerosis (MS). In these disorders, mainly CD8⁺ T-cells of putative specificity for myelin- and oligodendrocyte-related antigens are found, so that neuronal apoptosis in grey matter lesions may be a collateral effect of these cells. Different types of animal models are established to study the underlying mechanisms of the mentioned pathophysiological processes. However, although they mimic some aspects of MS, it is impossible to dissect the exact mechanism and time course of ‘‘collateral’’ neuronal cell death. To address this course, here we show a protocol to study the mechanisms and time response of neuronal damage following an oligodendrocyte-directed CD8⁺ T cell attack. To target only the myelin sheath and the oligodendrocytes, in vitro activated oligodendrocyte-specific CD8⁺ T-cells are transferred into acutely isolated brain slices. After a defined incubation period, myelin and neuronal damage can be analysed in different regions of interest. Potential applications and limitations of this model will be discussed.

Wprowadzenie

Death of oligodendrocytes and destruction of the myelin sheath accompanied by loss of neurons and axons are typical pathological findings in grey matter lesions in individuals suffering from multiple sclerosis (MS)^1,2. Cortical lesions can be divided so far in three different subtypes²: subpial, intracortical and leukocortical lesions. In comparison to white matter plaques, infiltrates are characterized by a predominance of CD8⁺ T-cells, suggesting their possible decisive role in grey matter inflammation³. Furthermore, oligoclonal expansions in blood, cerebrospinal fluid (CSF) and within inflammatory lesions can be found for CD8⁺ T-cells themselves^4-6.

In line with this, it is assumed that CD8⁺ T-cells may be specific for different myelin proteins^7,8. Indeed, CD8⁺ T-cells are found near oligodendrocytes and myelin sheaths^9,10 that show MHC I expression¹¹ and might therefore be responsible for the loss of the myelin sheath. This process is often seen together with extensive ‘‘collateral’’ neuronal and axonal damage within the central nervous system (CNS) grey matter^1,2. In fact, direct and indirect death of oligodendrocytes and neurons is induced by CD8⁺ T-cells via two different mechanism: (i) cell membrane swelling and rupture due to the formation of cytotoxic granules following the release of perforins and granzymes and (ii) ligation to the Fas receptors or exposition of FasL on their surface^8,12,13.

Different types of animal models are established to study the underlying mechanism of the mentioned processes. In this respect, primed CD8⁺ T-cells specific for autoantigens with induced expression in CNS glial cells, like oligodendrocytes or astrocytes, can be adoptively transferred to analyse ‘‘collateral’’ neuronal and axonal death in grey matter subsequently^14,15. To perform such in vivo experiments is a big help to mimic some pathophysiological aspects of MS, however, this approach is not suited to resolve the underlying mechanism and kinetics of axonal damage and neuronal apoptosis.

To overcome these restrictions, an ex vivo approach was established to study the mechanisms and time course of neuronal cell death following a oligondendrocytes-directed CD8⁺ T-cell attack. Since only oligodendrocytes and therefore myelin sheath production should be targeted by immune cells, MHC class-I-restricted, ovalbumin (OVA)-reactive OT-I Tcells are used¹⁶. These cells are subsequently transferred into brain slices obtained from mice selectively expressing OVA in oligodendrocytes (ODC-OVA mice)¹⁷.

Access restricted. Please log in or start a trial to view this content.

Protokół

All experiments using mice should be performed in accordance with the guidelines of the respective institutional animal care and use committee.

1. General Comments for Mouse Experiments

1. Keep the mice under pathogen-free conditions and enable them access to food and water ad libitum.
   NOTE: It is important to use age- and sex-matched mice in experimental groups because immunological patterns can vary with age and gender.

2. Preparation and Activation of OVA-specific CD8⁺ T-cells (OT-I)

1. Perform stimulation of OT-I T cells as described below 5 days before preparing brain slices.
   NOTE: 5 x 10⁵ activated effector CD8⁺ OT-I T-cells (CD8⁺ T-cells of transgenic mice recognizing only the OVA_257-264 peptide in the context of MHC-I molecules) are needed per slice The concentration 5 x 10⁵ was chosen experimentally as optimal one to favor a good cell-cell interaction once that the cells start migrating into the slice and, at the same time, the amount of cells is not too high to induce an overreaction allowing single cell counting^8,18.
2. Prepare the medium for culturing OT-I T-cells. Supplement 500 ml DMEM with 5% fetal calf serum (FCS), 10 mM HEPES, 2 mM L-glutamine, 50 µM 2-mercaptoethanol, 1% nonessential amino acids and 25 µg/ml gentamicin. Store the medium at 4 °C until use.
3. Remove the spleen of OT-I transgenic mice as per reference¹⁶. Transfer them into the prepared medium.
4. Generate single cell suspension by mashing spleens through a 70 µm strainer and centrifuge suspension at 300 x g for 5 min, 4 °C.
5. Incubate cell suspension with 5 ml ammonium-chloride-potassium (ACK) buffer (150 mM NH₄Cl, 10 mM KHCO₃, 0.1 mM EDTA, pH 7.3) for 5 min to lyse red blood cells.
6. Stop incubation with 10 ml medium and centrifuge it again as described above.
7. Dilute cell suspension in medium and calculate numbers. Plate cells at a density of 3 x 10⁷ cells/well in a 12-well plate and prime them by incubation with OVA_257–264 (SIINFEKL; 1 nM) and interleukin 2 (IL-2) (500 IU/ml) for 5 days.
8. After 4 days, add IL-2 at a concentration of 500 IU/ml again.
9. Subsequent to stimulation, purify OT-I T-cells from cell suspension by using a negative selection based mouse CD8⁺ T-cell isolation kit following manufacturer’s instructions. Purification is based on the depletion of all non-CD8⁺ cells by using a cocktail of antibodies against CD4, CD11b, CD11c, CD19, CD45R (B220), CD49b (DX5), CD105, MHC Class II, Ter-119, and TCRγ/δ which are then discarded by using magnetic columns for the elution of the purified CD8⁺ T-cells.
   NOTE: Critical steps in this procedure are indicated by the manufactures: it is important that the reaction involves only single cells because the presence of clumps could block the column during the elution step; counting of the cell before adding the Byotin cocktail is important for the degree of purity of the sample and the procedure should be performed on ice to minimize unspecific antibody bindings.

3. Preparation of Acute Brain Slices and Co-culture with OT-I T-cells

1. Prior to the preparation of acute brain slices¹⁹, prepare placedine ice-cold physiological saline solution using 200 mM sucrose, 20 mM PIPES, 2.5 mM KCL, 1.25 mM NaH₂PO₄, 10 mM MgSO₄, 0.5 CaCl₂ and 10 mM dextrose and artificial cerebrospinal fluid (ACSF) by using 125 mM NaCl, 2.5 KCl, 1.25 NaH₂PO₄, 24 mM NaHCO₃, 2 mM MgSO₄, 2 mM CaCl₂, 10 mM dextrose. Adjust pH of each solution to 7.35 by using NaOH. Before adjusting pH of ACSF, solution must be bubbled with a mixture of 95% O₂ and 5% CO₂.
2. Pre-cool the solutions.
3. Anesthetize 8 - 10 week old mice (e.g., C57Bl/6 as control or transgenic ODC-OVA mice¹⁷ with inhalation using 5.0% isoflurane, 5.0% halothane or inject 100 mg/kg ketamine and 10 mg/kg body weight xylazine via i.p. Wait for anesthesia and use a toe pinch to assess the level of anesthesia and decapitate them at once. Euthanize the mice as per institutional animal care and use committee criteria for euthanasia.
4. Put mouse in ventral position. Disinfect and cut scalp sagittally. Open the cranial bone sagitally, remove the brain quickly with the help of a scoop and fix it on the plate of a vibratome by using glue.
5. Fill the plate with the prepared placedine ice-cold physiological saline solution.
6. Cut 300 µm coronal slices with the vibratome.
   NOTE: This procedure is known to yield viable intact tissue specimens appropriate for functional cellular studies within a time interval of at least 8 hr^19-21. Indeed, after this time period, already starting after 6 hr, the preparation shows reduced quality, namely changes in basic and functional properties like action potential generation and propagation.
7. After sectioning, transfer one slice immediately into each well of a 12-well plate filled with ACSF.
8. Add carefully 5 x 10⁵ OT-I T cells per slice.
9. Incubate slices for up to 8 hr in an incubator (37 °C, 5% CO₂).
10. After the incubation period, harvest slices and embed them by using OCT compound tissue-tek and freeze them in liquid nitrogen. Store them at -20 °C for further histological studies to e.g., evaluate neuronal structure (e.g., using anti-MAPII or anti-synaptophysin antibodies) or apoptosis (e.g., using anti-Caspase-3 antibodies and anti-NeuN antibodies) according to standard procedures.

Access restricted. Please log in or start a trial to view this content.

Wyniki

After incubation of brain slices with oligodendrocyte-directed CD8⁺ T-cells, oligodendrocytes as well as neurons undergo apoptosis (Figures 2A and 1C, respectively). Histological signs of apoptosis (e.g., Caspase-3, Tunel) can be earliest detected after 3 hr of incubation. Incubation period should not be longer than 8 hr in order to guarantee a good quality of the preparation and reproducible results. Apoptotic cells can be found all over the slice with preponderance in myelinated are...

Access restricted. Please log in or start a trial to view this content.

Dyskusje

Different animal models have been described over the last decades to address the pathological features of inflammatory demyelinating disorders like MS. In vivo mouse and rat models are widely used to mimic pathophysiological features of the disease, namely, analysis of the consequences of demyelination and remyelination processes and of intermingled episodes of inflammation and neurodegeneration. Nevertheless, only an ex vivo approach allows to dissect the exact underlying mechanisms.

Access restricted. Please log in or start a trial to view this content.

Materiały

Name	Company	Catalog Number	Comments
12-Well plate	Corning	3513
2-Mercaptoethanol	Gibco	31350-010
2-Methylbutan	Roth	3927.1
70 µm strainer	Falcon	352350
CaCl2	Merck	1.02382.0500	calcium chloride
CD8+-isolation kit	Miltenyi Biotech	130-090-859
D(+)-glucose	Merck	1.08337.1000
DMEM	Gibco	31966-021	warm in 37 °C water bath before use
EDTA	Sigma	E5134
FCS	PAA Laboratories	A15-151	fetal calve serum
Gentamicin	Gibco	15750-060
HEPES 1 M	Gibco	15630-050
IL-2	Peprotech	212-12
Isofluran	Abbott	05260-05
KCl	Merck	1.04933.0500	potassium chloride
KHCO3	Sigma	P9144	potassium hydrogen carbonate
L-Glutamine	Gibco	35050-038
MgSO4	Merck	1.05886.0500	magnesium sulfate
NaCl	Sigma	31434	sodium chloride
NaH2PO4 * H2O	Merck	1.06346.0500	sodium hydrogen phosphate
NaHCO3	Merck	1.06329.0500	sodium hydrogen carbonate
NaOH	Merck	1.09137.1000	sodium hydroxide
NH4Cl	Sigma	213330	ammonium chloride
Non essential amino acid	Gibco	11140-050
OVA (257-264)	Genscript	RP10611	ovalbumin
PIPES	Sigma	P6757
Sucrose	Merck	1.07687.1000
Tissue-Tek OCT	Sakura	4583